Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 45.6% |
| 2 | Technology | 19.83% |
| 3 | Financials | 7.37% |
| 4 | Consumer Discretionary | 6.6% |
| 5 | Communication Services | 5.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
LYRA
4926
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $430 | ﹤0.01% |
48
-953
| -95% | -$7.91K |
2023 Q4
6 quarters
|
|
4927
Barclays
BCS
$79.1B
| $428 | ﹤0.01% |
23
| – | – |
2013 Q2
48 quarters
|
|
4928
iShares MSCI Sweden ETF
EWD
$942M
| $412 | ﹤0.01% |
9
| – | – |
2022 Q1
13 quarters
|
|
4929
Harvard Bioscience
HBIO
$38M
| $395 | ﹤0.01% |
89
-4,087
| -98% | -$17.1K |
2023 Q2
8 quarters
|
|
4930
United States 12 Month Oil Fund,
USL
$49M
| $386 | ﹤0.01% |
11
| – | – |
2020 Q1
21 quarters
|
|
4931
Unicycive Therapeutics
UNCY
$118M
| $382 | ﹤0.01% |
+80
| New | +$495 |
2025 Q2
0 quarters
|
|
|
ASPSW
4932
Altisource Portfolio Solutions SA Net Settle Stakeholder Warrants
ASPSW
$8.46M
| $343 | ﹤0.01% |
+686
| New | +$322 |
2025 Q2
0 quarters
|
|
|
DMRA
4933
Damora Therapeutics
DMRA
$1.27B
| $341 | ﹤0.01% |
100
-33
| -25% | -$98 |
2025 Q1
1 quarter
|
|
4934
Canterbury Park Holding Corp
CPHC
$81.6M
| $320 | ﹤0.01% |
+17
| New | +$301 |
2025 Q2
0 quarters
|
|
4935
AllianzIM U.S. Equity Buffer20 Jun ETF
JUNW
$382M
| $319 | ﹤0.01% |
10
-1,619
| -99% | -$49.1K |
2025 Q1
1 quarter
|
|
4936
Global Indemnity Group
GBLI
$356M
| $282 | ﹤0.01% |
9
| – | – |
2022 Q1
13 quarters
|
|
|
XELAP
4937
DELISTED
Exela Technologies, Inc. 6.00% Series B Cumulative Convertible Perpetual Preferred Stock
XELAP
| $274 | ﹤0.01% |
24,900
| – | – |
2024 Q4
2 quarters
|
|
|
TGE.WS
4938
The Generation Essentials Group Warrants
TGE.WS
| $274 | ﹤0.01% |
+686
| New | +$366 |
2025 Q2
0 quarters
|
|
|
PDYNW
4939
DELISTED
Palladyne AI Corp Warrants
PDYNW
| $190 | ﹤0.01% |
500
| – | – |
2022 Q1
13 quarters
|
|
|
RAPT
4940
DELISTED
RAPT Therapeutics
RAPT
| $176 | ﹤0.01% |
22
-4,350
| -99% | -$33.2K |
2022 Q1
13 quarters
|
|
4941
Inovio Pharmaceuticals
INO
$120M
| $167 | ﹤0.01% |
82
-36,327
| -100% | -$69.6K |
2024 Q2
4 quarters
|
|
4942
Outlook Therapeutics
OTLK
$144M
| $162 | ﹤0.01% |
101
-16,939
| -99% | -$27K |
2021 Q1
17 quarters
|
|
4943
Ondas Inc
ONDS
$4.22B
| $134 | ﹤0.01% |
+70
| New | +$78 |
2025 Q2
0 quarters
|
|
|
BBU
4944
DELISTED
Brookfield Business Partners
BBU
| $130 | ﹤0.01% |
5
-52
| -91% | -$1.22K |
2025 Q1
1 quarter
|
|
|
EMPD
4945
Empery Digital
EMPD
$86.2M
| $125 | ﹤0.01% |
18
-1
| -5% | -$6 |
2025 Q1
1 quarter
|
|
|
ASPSZ
4946
Altisource Portfolio Solutions SA Cash Exercise Stakeholder Warrants
ASPSZ
$7.05M
| $124 | ﹤0.01% |
+244
| New | +$126 |
2025 Q2
0 quarters
|
|
4947
DNA X Inc
SONM
$6.07M
| $122 | ﹤0.01% |
+6
| New | +$148 |
2025 Q2
0 quarters
|
|
4948
Main Street Capital
MAIN
$5.15B
| $118 | ﹤0.01% |
2
-59,283
| -100% | -$3.28M |
2024 Q2
4 quarters
|
|
4949
Innovator Power Buffer Step-Up Strategy ETF
PSTP
$134M
| $100 | ﹤0.01% |
3
-125
| -98% | -$3.98K |
2025 Q1
1 quarter
|
|
4950
Babcock & Wilcox
BW
$849M
| $97 | ﹤0.01% |
101
-54,723
| -100% | -$37.4K |
2022 Q1
13 quarters
|
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2025 filing shows 461 new, 2,914 increased, 1,345 reduced and 463 closed positions. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M. The largest sale was Honeywell, an estimated $1.54B.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 41% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.